Search the webpage

At Experimentica we dedicate a significant amount of state-of-the-art methods for defining broad array of ophthalmic indications.

Together with our partners from academia and industry we are participating in a number of extramurally funded research programs among others on diabetic retinopathy, development of artificial cornea and ocular surface diseases.

Please do not hesitate to contact us for further information at info@experimentica.com

PROJECTS

Development and validation of preclinical models for research of advanced therapeutics

In August 2018, Experimentica Ltd. announced the opening of a new Research & Development site in Vilnius, Lithuania, which will strengthen the company’s global position as a leader in the ophthalmic contract research organization market. The investment totaling €1.6 million was supported, in part, by a competitive award “Smart FDI” (project no. 01.2.1-LVPA-T-848-01-005) under the Promotion of Scientific Research, Experimental Development and Innovations Priority of the Operational Programme of the European Union Structural Funds for 2014-2020.

The funded research project “Development and validation of preclinical models for research of advanced therapeutics” is dedicated to developing and validating novel preclinical ophthalmic disease-specific models, enabled by novel research on the pathophysiological mechanisms and the use of non-invasive imaging modalities. The availability of these novel preclinical models will help bridge the gap between preclinical discovery of novel exosome-based advanced therapeutics for ocular diseases and their translation to the clinic.

R&D project on a novel diabetic retinopathy model

In 2017, Centre for Economic Development, Transport and the Environment, awards Experimentica Ltd. a funding of over 200,000 €.

The funding will aid the development of a novel murine diabetic retinopathy (DR) model and expansion of Experimentica’s laboratory animal centre (LAC) in Kuopio, Finland. The total sum of investments into DR-related R&D activities and LAC will be over 0.5 M€ during 2017-2019.

Eurostars PREVIN

Eurostars, an European funding programme has been approved an application for the development of a novel eye-drop drug for the preventive treatment of diabetic retinopathy under the project name “PREVIN” in consortium together with Experimentica Ltd., Medical University of Vienna, Nucro-Technics, University of Copenhagen and Zealand University Hospital.

The overall project budget covers a period of 36 months and amounts to EUR 2.1 million. Business Finland (formerly the Finnish Funding Agency for Technology and Innovation, Tekes) granted the Experimentica Ltd part of the R&D project over 150.000 €.

More details: https://www.eurostars-eureka.eu/project/id/11008

Young Innovative Company funding

Experimentica Ltd was selected to a Young Innovative Company (YIC) funding program, phase I, by Business Finland starting the beginning of 2018 to accelerate the global growth and to open up new markets in Asia, to development of business activities globally.

Business Finland provides funding for the most ambitious and rapidly growing innovative companies in Finland and currently there are only thirteen companies in the Life Sciences and Health professions supported by YIC funding.

LATEST NEWS

Meet us at SMi’s Ophthalmic Drugs Conference 2019 in London, UK, 2019

News
We are pleased to be a part of the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on ... Read More

Experimentica Ltd. is a member of BioMelbourne Network

News
We are delighted to become a member of BioMelbourne Network together with other committed organisations engaged in biotechnology, medical technology, ... Read More

Let’s meet at Global Biotech VIP Week in Melbourne, 2019

News
Experimentica’s CEO Giedrius Kalesnykas attends Global Biotech VIP Week in Melbourne, Australia, sponsored by Global Victoria, and participates in AusBiotech ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!